Back to dashboard
All PlansCoverageMedium impact

Functional Neuromuscular Electrical Stimulation

Regence BlueShield·Neurology, Physical Therapy, PM&R (Physical Medicine & Rehab) +1 more·Coding
Effective date
Jul 1, 2026
We identified it
Jul 7, 2026
Days to comply

Summary

This new policy (effective July 1, 2026) classifies all Functional Neuromuscular Electrical Stimulation (FNMES) devices and treatments as investigational for ALL indications, including spinal cord injury rehabilitation, stroke recovery, foot drop correction, and pain management. Billing teams must deny all claims for these devices and notify patients that they may be financially responsible.

Action Required

Action needed
By June 30, 2026: Billing team must implement the following changes: (1) Update billing system to automatically DENY all claims for Functional Neuromuscular Electrical Stimulation devices, including NMES, FNS, FES, ENS, and EMG-triggered neuromuscular stimulation; (2) Add these device types to the non-covered/investigational services list in the claims processing system; (3) Create a patient notification template informing patients that FNMES devices are investigational and not covered, and patients will be responsible for all costs; (4) Instruct providers and front desk staff to provide this notification BEFORE rendering any FNMES services; (5) Configure system to generate automatic patient financial responsibility forms for any FNMES claims received. Failure to implement these changes will result in inappropriate claim processing and potential compliance issues. Claims for FNMES devices should be processed as patient responsibility rather than insurance denial.